Epclusa vs. Vosevi, what is the difference?

epclusa vs vosevi

Epclusa and Vosevi are both prescription medications used to treat chronic hepatitis C virus (HCV) infection.

Epclusa is a combination of two antiviral drugs, sofosbuvir and velpatasvir, and is indicated for the treatment of all HCV genotypes (1-6).

Vosevi, on the other hand, is a combination of three antiviral drugs: sofosbuvir, velpatasvir, and voxilaprevir. It is indicated for the treatment of HCV genotypes 1-6 in patients who have previously been treated with a direct-acting antiviral (DAA) regimen, but did not achieve a sustained virologic response (SVR).

The main difference between Epclusa and Vosevi is that Vosevi contains an additional antiviral drug, voxilaprevir, which targets the HCV NS3/4A protease, another enzyme essential for HCV replication.

This additional drug provides a stronger antiviral effect against HCV in patients who have previously been treated but did not achieve an SVR.

In conclusion, both Epclusa and Vosevi are effective treatments for HCV infection, but the choice of medication will depend on the patient’s HCV genotype, previous treatment history, and overall health.

A healthcare provider should be consulted to determine the best treatment option for a specific patient.